Trellus Health (LSE:TRLS)
Historical Stock Chart

From Dec 2021 to Dec 2024

TIDMTRLS

RNS Number : 8916S

Trellus Health PLC

19 July 2022

Trellus Health plc

("Trellus Health" or the "Company")

Directorate Changes

LONDON, U.K. AND NEW YORK, U.S. ( 19 July 2022). Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, resilience-based, connected health solution for chronic condition management, announces the following Board and senior management changes:

-- Dr. Marla Dubinsky, Co-Founder, who has served the Company and its shareholders as a Non-executive Director since July 2020, will assume the role of CEO with immediate effect. To accommodate this new role, Dr. Dubinsky is reducing other commitments during her tenure as Trellus Health's CEO.

-- Aled Stevenson, currently US Executive VP of Sales and Development, will become Chief Operating Officer (a non-board position) with immediate effect.

-- Monique Fayad is standing down as CEO and from the Board of Trellus Health with immediate effect, and will continue to offer consultancy services to the Company for a six-month handover period.

-- Richard Evans, who has served as interim CFO since January 2022, has completed his contract and his duties have transitioned back to Salim Hamir, Company Secretary and formerly CFO, who is supported by the Company's financial controller. The Board is reviewing the needs of the business in terms of the finance function and expects to make a further appointment in due course.

Julian Baines, Non-executive Chairman of Trellus Health, said: "We are very grateful to Monique for her stewardship of Trellus Health through our Admission to AIM and the recent delivery of key milestones during very challenging market conditions and the evolution of our strategy. We wish her the best in her next venture. We also thank Richard for his support in reviewing key aspects of the delivery model and our Direct-to-Consumer (DTC) capability, and wish him well as he resumes his retirement.

"It remains our strategy to focus on both a DTC model as well as a Business-to-Business model to expand our customer base, and to add further r egional and national multi-year contracts with payers from 2023 onwards, as well as accelerating our expansion into other chronic conditions such as IBS . Marla's unrivalled expertise and reputation in this market means she is very well-placed to lead Trellus Health as we execute our commercialisation strategy."

About Dr. Marla Dubinsky

Marla Dubinsky, MD, is a Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Dubinsky received her medical degree from Queen's University, Canada. She completed her pediatric residency at Alberta Children's Hospital, Calgary, Canada, and her clinical fellowship in gastroenterology and nutrition at Sainte-Justine Hospital at the University of Montreal, Canada. She completed her research fellowship in IBD at Cedars-Sinai Medical Center in Los Angeles, CA, where she served as the Director of the Pediatric IBD Center before going to Mount Sinai as the Chief of Pediatric Gastroenterology and Nutrition at the Mount Sinai Kravis Children's Hospital and Co-Director of the Susan and Leonard Feinstein IBD Clinical Center. Dr. Dubinsky is also the Co-Director of the IBD Preconception and Pregnancy Planning Clinic at Mount Sinai. She is the Co-Founder of Mi-Test Health, and Cornerstones Health which is a non-profit organization dedicated to enhancing and transforming communication between health care providers, patients, and industry partners through creative, comprehensive, and expert-based educational program .

Dr. Dubinsky has been engaged in inflammatory bowel disease (IBD) clinical and translational research for over two decades. Dr. Dubinsky's primary research focuses on developing predictive models and web-based decision support tools that integrate clinical and biomarkers to predict the natural history of IBD and response to therapy. She has a keen interest in personalized medicine in IBD and her research uncovers predictors of rapid disease progression with the goal of preventing complications by altering treatment plans. Dr. Dubinsky is the principal investigator of multiple large longitudinal cohorts including the Road to Prevention Multiplex Family Program at Mount Sinai with over 700 enrolled participants with a goal of using multi-omic data to predict the development of IBD in unaffected family members and co-investigator of the Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn's Disease (RISK) study and senior author on the manuscript presenting a model to predict the natural history of pediatric Crohn's disease. Dr. Dubinsky is very committed to women's reproductive health in IBD and in addition to her research in this field she is the Co-founder of WECARE in IBD, an organization dedicated to the health of women with IBD. She has lectured widely, both nationally and internationally, and has published in more than 260 peer-reviewed journals, including Gastroenterology, Lancet, JAMA, The Journal of Pediatric Gastroenterology and Nutrition, The journal of Crohn's and Colitis, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology.

About Aled Stevenson, Chief Operating Officer

Aled Stevenson, formerly US Executive VP of Sales and Development at Trellus Health, joined Trellus Health a year ago after a successful 19-year career as a Regional Business Manager for AstraZeneca, serving initially as Managing Director, UK, before focusing on commercial activities in his sales and development role for the US market.

The resilience-based, connected health solution for chronic condition management is based on technology developed by Drs. Dubinsky and Keefer at Mount Sinai and licensed by Mount Sinai to Trellus Health. Mount Sinai and Mount Sinai faculty, including Dr. Dubinsky, have a financial interest in Trellus Health. Mount Sinai also has representation on the Trellus Health Board of Directors, which includes Dr. Dubinsky.

For further information please contact:

 
Trellus Health plc                                        www.trellushealth.com 
Julian Baines, Chairman                                         Via Walbrook PR 
 
Singer Capital Markets (Nominated                            Tel: 020 7496 3000 
 Adviser & Broker) 
Aubrey Powell / Jen Boorer 
 
Walbrook PR Limited                Tel: 020 7933 8780 or trellus@walbrookpr.com 
Paul McManus / Louis Ashe-Jepson            Mob: 07980 541 893 / 0 7747 515 393 
 

About Trellus Health plc (www.trellushealth.com)

Trellus Health (LSE: TRLS) is the first digital health company focused on the intersection of chronic physical conditions and mental health. Trellus Health integrates its proprietary resilience-based methodology with the technology, tools and team to deliver a whole-person technology-enhanced experience that results in relieving disease burden and promoting individual health behaviors that enable thriving in the face of a chronic condition. Through its TrellusElevate(TM) connected care platform and companion App, the company addresses both clinical and behavioral health together, in context, to improve outcomes and reduce healthcare costs for patients, employers, and the healthcare system.

The Company is initially focused on Inflammatory bowel disease ("IBD"), which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis, but considers its approach to have potential utility and demand across many chronic conditions, including Irritable Bowel Syndrome ("IBS").

The TrellusElevate(TM) platform is the Company's proprietary connected health platform that incorporates the GRITT(TM) methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers. IBD patients treated using the methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following program completion (source: https://www.sciencedirect.com/science/article/pii/S1542356521012258 ).

The Company was founded by Mount Sinai faculty members Dr. Marla C. Dubinsky, MD and Dr. Laurie Keefer, PhD, both with decades of combined experience in IBD and psychogastroenterology, respectively. Trellus Health's patent-pending GRITT(TM) resilience assessment and personalized treatment methodology was developed and validated at the Mount Sinai Health System to build resilience and wellness for improved outcomes at lower cost.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information on Trellus Health, visit: www.trellushealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOADZGMNZRGGZZZ

(END) Dow Jones Newswires

July 19, 2022 02:00 ET (06:00 GMT)